Company Overview
NewLimit is a biotechnology company leading the charge in extending human healthspan through epigenetic reprogramming. The company specializes in developing novel medications aimed at restoring youthful function in aged cells by reprogramming the epigenome. NewLimit's pioneering work focuses on treating age-related diseases and addressing large unmet medical needs, positioning it as a leader in therapeutic interventions for longevity.
Mission and Approach
The mission of NewLimit is to improve the quality of health during aging, not merely to increase lifespan. By leveraging advanced scientific methodologies, including single-cell genomics and machine learning, NewLimit aims to effectively understand and manipulate cellular aging processes. The company is actively involved in developing therapies to regenerate tissues and rejuvenate cell functions, thereby providing solutions to age-related diseases.
Leadership and Key Personnel
NewLimit's leadership team consists of highly skilled individuals with diverse backgrounds in biotechnology, machine learning, and operations.
- Blake Byers: Co-founder with a PhD and MS in Bioengineering from Stanford University. Former General Partner at GV, his background in investments in technology and healthcare sectors provides strategic guidance to NewLimit.
- Brian Armstrong: Co-founder, known for founding and leading Coinbase. His expertise in software and machine learning supports NewLimit’s mission. He holds a Master’s in Computer Science and a Bachelor’s in Economics from Rice University.
- Jacob Kimmel: Head of Research, PhD in Stem Cell Biology from the University of California, San Francisco. He specializes in genomics and machine learning for genetic reprogramming approaches.
- Cathy O’Hare: Head of Operations with a PhD in Neuroscience from the University of California, San Francisco. She focuses on fostering a productive organizational culture and has extensive experience in developing medicines and diagnostics.
Scientific and Advisory Team
NewLimit’s scientific endeavors are bolstered by a team of distinguished advisors:
- Alex Marson: Professor at UCSF, CRISPR technology expert focusing on immunology.
- E. John Wherry: Renowned for work on T cell exhaustion and cancer therapies.
- Hao Zhu: Specializes in oncological research and liver regenerative medicine.
- Mark M. Davis: Immunology expert with significant contributions to T-cell receptor understanding.
- Markus Grompe: Leader in cell and gene therapy development.
Financial Overview
NewLimit has secured $250 million in funding over several rounds with notable backing from investors such as Dimension, Founders Fund, and Kleiner Perkins. This financial support is crucial for advancing its ambitious goals in therapeutic research and development.
Competitor Profiling
Key Competitors
NewLimit operates within the biotechnology and anti-aging sectors with a focus on epigenetic reprogramming. Key competitors include:
1. Cellectis: A clinical-stage biopharmaceutical company using gene editing technologies like TALEN® for cancer immunotherapy.
2. Editas Medicine: Specializes in CRISPR gene editing for developing genomic medicines targeting serious diseases.
3. Illumina: A leader in genomic sequencing and array-based technologies essential for precision medicine.
4. Turn Biotechnologies: Focuses on mRNA medicines to address age-related diseases using the ERA™ platform.
5. Retro Biosciences: Aims to extend healthy lifespan by 10 years through cellular reprogramming and therapies targeting aging mechanisms.
Competitive Landscape
NewLimit's competitors operate at the nexus of gene editing, genomic analytics, and regenerative medicine. Their approaches:
- Cellectis offers advanced gene editing, particularly in cancer treatment.
- Editas Medicine focuses on personalized medicine through CRISPR technology.
- Illumina is pivotal in genetic analysis for disease treatment.
- Turn Biotechnologies leverages molecular advancements in mRNA medicines.
- Retro Biosciences emphasizes longevity products and services similar to NewLimit's pursuits.
This competitive environment showcases diverse expertise, characterizing a rapidly evolving biotechnology market. NewLimit's ongoing efforts in epigenetic reprogramming position it strategically among these dynamic competitors.
